Results from the ADAPT-DES registry definitely demonstrate that high platelet reactivity after implantation of drug-eluting stents is an independent predictor of one-year stent thrombosis
and heart attack, but it is also protective against major bleeding, both of which impact mortality," lead investigator Gregg W.
At the end of follow-up, definite or probable stent thrombosis
had occurred in 61 (1.
academic research consortium (ARC) definition of stent thrombosis
was used -
The management of antiplatelet therapy extracted related to the cessation or continuation of aspirin or clopidogrel and the substitution of any other agents to reduce the likelihood of stent thrombosis
is an uncommon, but potentially catastrophic complication that may occur after a stent has been inserted into a patient s coronary artery and causes clots to form.
The incidence of stent thrombosis
averages 1-2% over the first year but is greatest in the first month regardless of the type of stent used (15, 16).
The overall rate of definite or probable stent thrombosis
(ST) was 1.
The low stent thrombosis
rate demonstrated by XIENCE V is impressive given the complexity of the patient population included in the XIENCE V USA trial, and confirms that the stent thrombosis
results seen with XIENCE V in earlier randomized clinical trials are consistent in real-world clinical practice," said James Hermiller, M.
Longer-term data will be necessary to be sure about the late stent thrombosis
risk and safety, but clearly the data that we have now are very positive, and most interventionalists will view the new stents as steps forward," added Dr.
years with a primary endpoint of very late stent thrombosis
(ARC defined) and a
ADAPT-DES had previously demonstrated an approximately four times greater rate of stent thrombosis
at 30-days in patients with high residual platelet reactivity (HRPR), as measured by Accumetrics' VerifyNow P2Y12 Test.
In addition, the supplemental New Drug Application (sNDA) for the use of rivaroxaban, in combination with standard antiplatelet therapy, to reduce the risk of stent thrombosis
in patients with ACS has been resubmitted.